Multiple Myeloma News


Here are all the latest news articles written by The Beacon’s staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Sep 3, 2014 7:39 am | 9 Comments ]
Dyclonine, The Active Ingredient In Sucrets, May Enhance The Anti-Myeloma Activity Of Velcade

Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.

Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States.  Sucrets lozenges are marketed by Insight Pharmaceuticals.

The Karmanos researchers conducted laboratory tests of dyclonine’s activity against the so-called “RPMI8226″ line of myeloma cells, which is commonly used in pre-clinical testing of potential myeloma therapies. …

Read the full story »
[ by | Aug 27, 2014 9:52 pm | 6 Comments ]
OncoPep Begins Sponsorship Of The Myeloma Beacon

OncoPep, a biotech company developing a potential therapeutic vaccine for multiple myeloma, is the Myeloma Beacon’s newest pharmaceutical industry sponsor.

OncoPep was founded in 2010 to develop novel cancer immunotherapies that stimulate a patient’s own immune system to attack cancer cells. The company’s first investigational immuno­therapy is PVX-410, a cancer vac­cine based on re­search in the laboratory of Dr. Kenneth Anderson and Dr. Nikhil Munshi at the Dana-Farber Cancer Institute in Boston.

“OncoPep’s decision to support The Myeloma Beacon is yet another ex­ample of a forward-looking organi­za­tion finding itself aligned …

Read the full story »
[ by | Aug 26, 2014 1:26 am | 2 Comments ]
MRI Of The Spine Identifies Smoldering Myeloma Patients At High Risk Of Progressing To Multiple Myeloma

A recently published Greek study provides updated data on the sig­nif­i­cance of MRI-detected focal lesions in the spine in patients with smol­der­ing myeloma.

The Greek study confirms that having more than one focal lesion in the spine puts a smoldering myeloma patient at a noticeably higher risk of progressing to multiple myeloma.

Focal lesions are areas of abnormal cells in the bone marrow. They are not lesions in the outer (hard) area of the bone – lesions which are often called “lytic” lesions.

The Greek researchers found that the smoldering …

Read the full story »
[ by | Aug 17, 2014 4:10 pm | 5 Comments ]
Kyprolis Fails To Provide Overall Survival Benefit In FOCUS Phase 3 Trial

Amgen has given a first glimpse of key results from its FOCUS Phase 3 clinical trial testing Kyprolis in relapsed and refractory multiple myeloma patients.

The company reported this past Wednesday that Kyprolis did not provide an overall survival advantage in the trial, which is being con­ducted out­side the United States.

In addition, the company noted that patients treated with Kyprolis during the trial experienced more kidney-related side effects than patients who were not treated with the drug.

Up until recently, the primary significance of the FOCUS trial would have …

Read the full story »
[ by | Aug 11, 2014 4:48 pm | 22 Comments ]
Remembering Stephen Kramer

Another valued voice of the myeloma community has been lost.

Stephen P. Kramer, author of the Beacon column “Manhattan Tales,” passed away last Friday, August 8, at Memorial Sloan-Kettering Cancer Center in New York City. Stephen was 66 years old, and was diagnosed with multiple myeloma in early 2010.

At the time of his diagnosis, Stephen was working as Chief of Staff and Special Counsel to the Commissioner of the New York City Department of Buildings. This position was the culmination of a successful legal career that stretched back across …

Read the full story »
[ by | Aug 6, 2014 3:57 pm | One Comment ]

Constellation Pharmaceuticals recently initiated a Phase 1 clinical trial that will test whether single-agent CPI-0610 is safe and effective as an anti-myeloma therapy.

The clinical trial is taking place at a several locations across the United States, and is open to multiple myeloma patients who have relapsed after at least one previous myeloma treatment regimen.

CPI-0610 is a small molecule that inhibits bromodomain and extra-terminal (BET) proteins, which are involved in regulating the cell cycle and cell death. Bromodomain inhibitors, which include the compound JQ1, have attracted attention in recent years as potential treatments for a range of different cancers, including multiple myeloma.

A Phase 1 clinical trial of CPI-0610 as a potential treatment for lymphoma has been ongoing since last summer. The Phase 1 trial in myeloma and another Phase 1 trial in patients with acute leukemias and myelodysplastic syndromes have been added based on preclinical research showing blood-related cancers may be highly sensitive to BET inhibition.

For more information about the trial, see the trial description at the U.S. clinical trial registry.